Scholars Central

Conference abstractPublished 27 Jun 2016

Evaluating immunogenicity in biosimilars

Authors: Candida Fratazzi

BBCR Consulting, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Adoption of biosimilars is increasingly attractive to payers around the globe due to the mounting financial pressure from high expenditures on medical treatments. Clinical evaluation of comparative immunogenicity constitutes an important component of the regulatory review for biosimilar candidates. The anti-drug antibody formations are interpreted, during the review process, in relation to pharmacokinetics, pharmacodynamics, efficacy, and safety parameters. Evaluation of the immunogenicity associated with the biosimilar includes its negative impact on clinical relevant outcomes compared with the innovator product. Unwanted immunogenicity may lead to clinical consequences such as reduced or loss of efficacy, altered pharmacokinetics (PK), general immune and hypersensitivity reactions, and neutralisation of the natural counterpart (e.g. the physiological hormone). Relevant areas of discussion are: Testing strategies for immunogenicity assessment; and scientific progress on the product-related factors that may contribute to the development of immunogenicity, in particular that are related to protein aggregation and post-translational modifications. For chronic administration products, immunogenicity monitoring is required for a 12-month period of continuous treatment. Furthermore, the anti-drug antibody titers (i.e., erythropoietin, growth hormone, follitropin-alfa) interpretation is influenced by product quality differences and supported by a single-dose comparative pharmacokinetic study in healthy volunteers. The acceptance margins of detected ADA incidence for the biosimilar candidate versus the innovator product have not yet been defined by EU regulators. Indeed, until now, there is no standard bioanalytical assay sensitivity adopted nor any generalization has been made on the negative influence of clinical evidence on ADA incidence. In conclusion, immunogenicity and ADA evaluation are both complex processes that start during pre-clinical comparability and continue throughout pre approval and post-approval monitoring.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Candida Fratazzi”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels